Search
Isatuximab
go.drugbank.com/drugs/DB14811ApprovedInvestigational[L12099] It is a cytolytic antibody targeted against CD38, a glycoprotein found on the surface of some immune cells that is highly expressed by malignant plasma cells in multiple myeloma. … Following three consecutive years on the yearly "Antibodies to watch" list published in "mAb", a peer-reviewed scientific journal dedicated to antibody research,[A38676,A191826,A191829] isatuximab was
Anthralin
go.drugbank.com/drugs/DB11157ApprovedAnthralin (1,8‐dihydroxy‐9anthrone, dithranol) is an older anti-psoriatic agent that was first synthesized as a derivative of chrysarobin, obtained from the araroba tree in Brazil over 100 years ago. … Anthralin has also been studied in the treatment of warts, showing promising results [A32307].
Ofatumumab
go.drugbank.com/drugs/DB06650ApprovedInvestigational[L12612] Ofatumumab works by recognizing antigens that are expressed on the tumour cells in certain cancers; however, the antigen is not tumour-specific and can also be found in normal B-cells. … [L12771] It is used in the treatment of recurrent, progressive, or recurrent chronic lymphocytic leukemia (CLL) or CLL in treatment-naive patients in whom fludarabine-based therapy is considered inappropriate
Products: KESIMPTA SOLUTION FOR INJECTION IN PRE-FILLED PEN 20MG/0.4ML, Bonspri 20mg/0.4mL Solution for Injection in Pre-filled syringeMilnacipran
go.drugbank.com/drugs/DB04896ApprovedInvestigationalimportant role in the mitigation of pain signals in the descending inhibitory pain pathways in the brain and spinal cord [A175759, A175843, A175846]. … Milnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) and like many agents in this category was originally developed for and continues to be approved and indicated for the treatment
Polidocanol
go.drugbank.com/drugs/DB06811ApprovedInvestigationalPolidocanol is a sclerosing agent indicated to treat uncomplicated spider veins (varicose veins ≤1 mm in diameter) and uncomplicated reticular veins (varicose veins 1 to 3 mm in diameter) in the lower … The formula for Polidocanol has the structural formula C12H25(OCH2CH2)nOH, a mean extent of polymerization (n) of approximately 9 and a mean molecular weight of approximately 600.
Categories: Compounds used in a research, industrial, or household settingSamidorphan
go.drugbank.com/drugs/DB12543ApprovedInvestigationalSamidorphan has been shown in animal models and clinical trials to ameliorate [olanzapine]-induced weight gain and metabolic dysfunction. … [Olanzapine] is an effective atypical antipsychotic that, like other antipsychotics, is associated with weight gain, metabolic dysfunction, and increased risk of type II diabetes.
Etuvetidigene Autotemcel
go.drugbank.com/drugs/DB17593ApprovedInvestigationalEtuvetidigene autotemcel is an autologous gene therapy which includes hematopoietic stem cells (HSCs) that have been genetically modified ex vivo. … [A274878] The WAS protein is expressed on non-erythroid hematopoietic cells and regulates the function of actin filaments in the cytoskeleton.[A274878]
Avatrombopag
go.drugbank.com/drugs/DB11995ApprovedInvestigational[F95] Avatrombopag was first approved by the FDA in May 2018 for use in adults with chronic liver disease who are scheduled to undergo a procedure. … Avatrombopag (_Doptelet_), is an orally administered, small molecule thrombopoietin receptor (c-Mpl) agonist that increases platelet number without increasing platelet activation,[A33097,L2824] thereby
Solifenacin
go.drugbank.com/drugs/DB01591ApprovedInvestigational[L7511] Solifenacin was granted FDA approval on 19 November 2004.[L7511] … Solifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency.
Categories: Drugs Used in Benign Prostatic HypertrophyDiphenoxylate
go.drugbank.com/drugs/DB01081ApprovedIllicitInvestigationalA meperidine congener used as an antidiarrheal, usually in combination with atropine. At high doses, it acts like morphine. … This medication is classified as a Schedule V under the Controlled Substances Act by the Food and Drug Administration (FDA) and the DEA in the United States when used in preparations.